Competition

French Competition Authority launches sector inquiry into medicinal products and biomedical laboratories

Eveline Van Keymeulen

On 20 November 2017, the French Competition Authority (FCA) launched a sector inquiry into medicinal products and medical biology (biomedical) laboratories in France.  As previously announced, the inquiry aims to address the challenges that the sector entails for the French insurance system and public health and to assess the feasibility of more competitive conditions with Read More

Italy unlocks corporate investments in retail pharmacies

Eveline Van Keymeulen

On 29 August 2017, significant regulatory changes allowing corporate entities to own retail pharmacy businesses will enter into force in Italy.  The new measures bring attractive opportunities for corporate investors, opening to new business models for Italian pharmacies that already exist in other EU countries, such as corporate-owned pharmacy retail chains.  To date, Italian law Read More

French Supreme Court confirms discriminatory abuse in market of medical information databases for pharmaceutical companies

Eveline Van Keymeulen

Earlier this summer, the French Supreme Court (Cour de Cassation) rejected an appeal by Cegedim against a ruling of the Paris Court of Appeal, upholding a July 2014 decision of the French Competition Authority (FCA) that imposed a EUR 5.7 million fine on the company. The FCA had found that Cegedim’s refusal to grant a Read More

French Competition Authority announces healthcare sector enquiry during presentation of 2016 Annual Report

Eveline Van Keymeulen

The President of the French Competition Authority (FCA), Isabelle de Silva, recently confirmed in a radio interview the forthcoming launch of a sector-wide enquiry into the healthcare sector, with a special focus on hospital procurement, biomedical laboratories and pharmacies.  The enquiry aims to address the major economic and financial challenges that the sector entails for the Read More

Excessive pricing of medicines and antitrust: not a great week for Aspen

Eveline Van Keymeulen

This week Aspen received two pieces of bad news. On 13 June, the South African Competition Commission (SACC) announced the opening of an investigation against Aspen for its suspected excessive prices in the provision of certain cancer medicinal products (Leukeran, Alkeran and Myleran). The following day, the Italian administrative court of Lazio rejected the appeal Read More